Publication date: Dec 09, 2025
Nontuberculous mycobacteria (NTM) are opportunistic pathogens, and the global incidence of NTM diseases has been steadily increasing, posing significant public health challenges. This study retrospectively analyzed clinical data from 136 cases of NTM disease diagnosed at the Zhejiang Provincial Tuberculosis Diagnosis and Treatment Center between 2019 and 2022. It was observed that NTM diseases in this region predominantly affected middle-aged and elderly men, with chronic cough being the principal symptom (74. 3%). Bronchiectasis (57. 4%) and cavities (38. 2%) were the main imaging characteristics. The results of species identification demonstrated that Mycobacterium intracellulare (62. 5%) was the dominant strain. Antimicrobial susceptibility testing revealed that Mycobacterium avium complex exhibited relatively favorable sensitivity to clarithromycin, amikacin, ethambutol, rifapentine, rifampicin, and moxifloxacin, while the Mycobacterium chelonae/Mycobacterium abscessus complex showed sensitivity only to amikacin (66. 7%). In total, 66. 2% of patients received anti-NTM therapy. Patients completing ≥6 months of treatment achieved significantly higher efficacy than those with
| Concepts | Keywords |
|---|---|
| China | antimicrobial susceptibility test |
| Global | nontuberculous mycobacteria |
| Mycobacterium | NTM clinical characteristics |
| Therapy | NTM species identification |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | MESH | chronic cough |
| disease | MESH | Bronchiectasis |
| disease | MESH | strain |
| drug | DRUGBANK | Clarithromycin |
| drug | DRUGBANK | Amikacin |
| drug | DRUGBANK | Ethambutol |
| drug | DRUGBANK | Rifapentine |
| drug | DRUGBANK | Rifampicin |
| drug | DRUGBANK | Moxifloxacin |